Special Issue

Personalized Medicine for Neuromuscular Atrophy

Message from the Guest Editor

The field of neuromuscular disorders has made great advances in the last decade, owing to the discovery of key mechanisms attributed to the pathogenesis and many innovative tools which facilitate its diagnosis and molecular characterization. Together, this has culminated in various treatment strategies for diseases such as Spinal Muscular Atrophy and Duchenne Muscular Dystrophy. However, many questions remain unresolved, including the contribution of other tissues to the disease onset and progression, the mechanism to explain the heterogeneity of disease manifestation and the variability in drug response. This Special Issue aims to embody the recent findings covering from basic science to therapeutic strategy to address the current challenges in the molecular characterization of neuromuscular diseases and their therapeutic approaches. We are encouraging submissions focusing on, but not limited to, emerging technologies and approaches to reveal aberrant molecular mechanisms and novel advancements to ameliorate the state-of-art therapies.

Guest Editor

Dr. Piera Smeriglio

Center of Research in Myology, Sorbonne University, UMRS974, INSERM-AIM, Paris,France

Deadline for manuscript submissions

closed (30 September 2022)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/61970

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

MDPI

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).